Dr. White Describes the BR-002 Trial in Breast Cancer

Julia White, MD
Published Online: Thursday, May 22, 2014
Julia White, MD, professor, director, Breast Radiation Oncology, vice chair, Clinical Research, The Ohio State University Comprehensive Cancer Center, describes the BR-002 trial for patients with breast cancer.

This trial seeks to confirm that a local intervention does not change the outcome of a patient, White says. Participants of the trial will be informed that the regular treatment for metastatic breast cancer is systemic therapy and locoregional therapy is reserved if there is a problem. Patients will be randomized to ablation to other areas of metastases or standard treatment.

Women are only qualified for the trial if they are responding to chemotherapy or are in their first line of chemotherapy and are relatively healthy.

Online CME Activities
Free CME from PER
B-Cell Malignancies: Novel Agents, Emerging Treatment Strategies, and the Revolution of Care
Community Practice Connections: 15th Annual International Lung Cancer CongressĀ®
Community Practice Connections: 13th Annual International Congress on the Future of Breast CancerĀ®
Highlights From the 13th Annual International Congress on the Future of Breast CancerĀ®
More Reading
$auto_registration$